John C. Reed - 01 May 2026 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Reporting relationship: EVP, Innovative Medicine, R&D
Issuer ticker: JNJ
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 May 2026, 16:58:59 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Joleen Morgan, as attorney-in-fact for John C. Reed

Key filing fact

John C. Reed filed Form 4 for JOHNSON & JOHNSON (JNJ) on 04 May 2026.

Key facts

This page summarizes John C. Reed's Form 4 filing for JOHNSON & JOHNSON (JNJ).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 May 2026, 16:58.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001181561 Primary reporting owner

REED JOHN C

Relationship: EVP, Innovative Medicine, R&D
Address: ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK
Signature: /s/ Joleen Morgan, as attorney-in-fact for John C. Reed
Signature date: 04 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JNJ transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,255
Change %: +237%
Price: $0.000000^*
Shares after: 35,913
Date: 01 May 2026
Ownership: Direct
Footnotes: F1

JNJ transaction

Common Stock

Tax liability

Transaction value
Shares: -11,002
Change %: -31%
Price: $229.85^*
Shares after: 24,911
Date: 01 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JNJ transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -25,255
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,255
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting.

Footnote F2

Shares withheld for payment of taxes upon vesting of RSUs.